The effects of combination of moderate-intensity statin and ezetimibe compared to high-intensity statin alone on coronary plaque regression in patients with percutaneous coronary interventio
- Conditions
- Endocrine, nutritional and metabolic diseases
- Registration Number
- KCT0003431
- Lead Sponsor
- Gachon University Gil Medical Center
- Brief Summary
ot applicable
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 23
Inclusion criteria
1) Patients with coronary artery disease who were 19 years of age or older and needed coronary angiography
2) Patients who needed percutaneous coronary intervention for coronary artery disease
3) Intermediate coronary artery stenosis (diameter stenosis =30% to =60% by visual estimation, diameter =2.0 mm to =4.0 mm, de novo lesion in native coronary artery) in which intravascular ultrasound could be feasible
4) Baseline serum LDL-C = 70mg/dL
5) Patients who gave written informed consent
Exclusion criteria
1) Cardiogenic shock
2) Heart failure with symptoms of New York Heart Association class III/IV or left ventricular ejection fraction <35%
3) Renal dysfunction (creatinine level =1.7 mg/dL or dependence of dialysis
4) Pregnancy or breast-feeding women
5) Psychotic patient
6) Hepatic dysfunction (transaminase level > 3 times of normal within limit)
7) Patients with difficulty in assessing intravascular ultrasonography for the following reasons: severe calcification, severe tortuous vessels, total occlusion
8) Patients who can not receive adequate antiplatelet therapy
9) Thrombocytopenia (platelet count < 70x109/L)
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent atheroma volume of intermediate in the vascular wall of the mild and intermediate stenosis lesion after 12months Lipid-lowering Drug
- Secondary Outcome Measures
Name Time Method Percent atheroma volume in the vascular wall;Lipid core burden index;Absolute and percent changes in the lipid, glycemic and inflammatory profiles